文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

英夫利西单抗治疗炎症性肠病的临床药代动力学与药效学

Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

英夫利西单抗是首个获批用于中重度活动性克罗恩病和溃疡性结肠炎的生物制剂,可诱导并维持临床缓解与黏膜愈合。其分布容积低、半衰期约14天,清除率个体间和个体内变异大,受抗药抗体、联用免疫调节剂、炎症程度、血清白蛋白和体重影响。本文综述其临床药代动力学、药效学及治疗药物监测在IBD中的作用。

要点

  • 英夫利西单抗按体重静脉给药,稳态分布容积4.5–6 L,中位半衰期约14天
  • 清除率变异受抗药抗体、联用免疫调节剂、炎症程度、白蛋白和体重影响
  • 治疗药物监测有助于优化IBD患者的英夫利西单抗治疗

核心结论

  • 英夫利西单抗的药代动力学在IBD患者中个体间和个体内变异大,抗药抗体、联用免疫调节剂、炎症程度、血清白蛋白和体重是清除率变异的部分解释因素。

研究设计与样本

  • 本文为综述,汇总英夫利西单抗在克罗恩病和溃疡性结肠炎患者中的临床药代动力学与药效学数据及治疗药物监测的作用。

主要发现

  • 英夫利西单抗稳态分布容积为4.5–6 L,中位半衰期约14天。
  • 群体药代动力学模型显示英夫利西单抗浓度-时间数据在个体内随时间及个体间高度变异。
  • 抗药抗体、联用免疫调节剂、全身炎症程度、血清白蛋白浓度和体重被识别为清除率变异的协变量,可影响药效学应答。

临床怎么用

  • 英夫利西单抗按体重静脉给药,临床可结合治疗药物监测优化IBD治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). It has been shown to induce and maintain both clinical remission and mucosal healing in pediatric and adult patients with inflammatory bowel disease (IBD) who are unresponsive or refractory to conventional therapies. The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of infliximab is low and at steady state ranges from 4.5 to 6 L. Therapeutic monoclonal antibodies, such as immunoglobulins, are cleared from the circulation primarily by catabolism. Median infliximab half-life is approximately 14 days. Infliximab concentration-time data in patients with CD and UC have been shown to be highly variable within an individual patient over time and between individuals by multiple population pharmacokinetic models. Covariates that have been identified to account for a part of the observed inter- and intra-individual variability in clearance are the presence of antidrug antibodies, use of concomitant immunomodulators, degree of systemic inflammation, serum albumin concentration, and body weight, which can affect the pharmacodynamic response. This article provides a comprehensive review of the clinical pharmacokinetics and pharmacodynamics of infliximab, as well as the role of therapeutic drug monitoring in the treatment of IBD.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet. 2018. PMID: 29330783. doi:10.1007/s40262-017-0627-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。